Sana to Present UP421 Allogeneic Islet Cell Data at EASD Meeting
SANA•Sana Biotechnology will present clinical data from a first-in-human UP421 allogeneic islet cell therapy using its hypoimmune platform transplanted without immunosuppression into a type 1 diabetes patient. The ‘Stem cell-derived islets in clinical trials’ symposium is set for October 2 at the EASD Annual Meeting 2026 in Milan.
1. Symposium Presentation Scheduled
Sana Biotechnology will showcase its research at the European Association for the Study of Diabetes Annual Meeting in Milan on October 2, 2026, from 9:10 to 9:30 a.m. CEST, during a session titled ‘Stem cell-derived islets in clinical trials: towards a cure for type 1 diabetes.’
2. First-in-Human UP421 Data
The company will highlight results from an investigator-sponsored, first-in-human trial transplanting UP421—an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform—into a type 1 diabetes patient without the use of immunosuppression.
3. Potential Impact on Diabetes Treatment
By engineering immune evasion into transplanted islets, Sana aims to deliver durable cell replacement without lifelong immunosuppression, potentially advancing a curative approach for type 1 diabetes.
